Patients with a higher thromboembolic risk gain the most benefits from concomitant SA, with patients at higher thromboembolic risk gaining the most benefits from concomitant SA.
Mariusz Kowalewski, G. Raffa, Jakub Batko et al.· Innovations· 0 citations
Current evidence supports a shift from generalized antioxidant supplementation toward mechanism-matched intervention in biologically selected patients, with the greatest credibility achieved when the active molecular species, dominant mechanism, cardiovascular phenotype, disease stage, clinically relevant exposure, mol...
Siwon Baek, M. Kang, G. Raffa et al.· Antioxidants· 0 citations
Findings establish ADAR enzymes as candidates tissue biomarkers of TAA severity and ADAR1 as the principal driver of epitranscriptomic dysregulation in MFS aortopathy.
Calogera Pisano, A. Colopi, Domenico Alessandro Silvestris et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.